Journal ArticleOPEN ACCESS

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

  • Gendron N
  • Feral‐Pierssens A
  • Jurcisin I
  • et al.
Clinical Case Reports (2017) 5(3) 346-350
DOI: 10.1002/ccr3.839
N/ACitations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.

Cite

CITATION STYLE

APA

Gendron, N., Feral‐Pierssens, A. L., Jurcisin, I., de Raucourt, E., Bouton, V., Fischer, A. M., … Smadja, D. M. (2017). Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding. Clinical Case Reports, 5(3), 346–350. https://doi.org/10.1002/ccr3.839

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free